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Histone Deimination Antagonizes
Arginine Methylation
ture and function. An important development in our un-
derstanding of these modifications has been the realiza-
tion that they are dynamic. The levels of histone
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We have previously proposed that arginine deimina-
tion, a process involved in the biosynthetic processing
Summary of free arginine, may occur on arginine residues in his-
tones or act to reverse arginine methylation (Bannister
Methylation of arginine residues within histone H3 has et al., 2002). Deimination results in the conversion of
been linked to active transcription. This modification arginine into citrulline (Figure 1A). Using an antibody
appears on the estrogen-regulated pS2 promoter that recognizes a modified form of citrulline, Hagiwara
when the CARM1 methyltransferase is recruited dur- et al. (2002) have shown that citrulline is present in a
ing transcriptional activation. Here we describe a pro- number of cellular proteins including histones. Enzymes
cess, deimination, that converts histone arginine to that may carry out the conversion of peptidyl arginine to
citrulline and antagonizes arginine methylation. We citrulline include a family of peptidyl arginine deiminases
show that peptidyl arginine deiminase 4 (PADI4) spe- (PADIs) that can deiminate arginines in cellular proteins
cifically deiminates, arginine residues R2, R8, R17, and (Nakashima et al., 2002; Vossenaar et al., 2003). We
R26 in the H3 tail. Deimination by PADI4 prevents argi- argued that if such deiminating enzymes function on
nine methylation by CARM1. Dimethylation of argi- methylated arginine within histones, they may effectively
nines prevents deimination by PADI4 although mono- act as arginine-specific demethylases (Bannister et
methylation still allows deimination to take place. al., 2002).
In vivo targeting experiments on an endogenous pro- Here, we report the identification of PADI4 as a histone
moter demonstrate that PADI4 can repress hormone H3 specific arginine deiminase. This enzyme can de-
receptor-mediated gene induction. Consistent with a iminate unmodified arginine and monomethyl (but not
repressive role for PADI4, this enzyme is recruited to
dimethyl) arginine. It functions as a transcriptional re-
the pS2 promoter following hormone induction when
pressor of the hormone-signaling pathway. PADI4 re-
the gene is transcriptionally downregulated. The re-
cruitment and H3 deimination occur during hormonecruitment of PADI4 coincides with deimination of the
signaling to the pS2 promoter during transcriptionalhistone H3 N-terminal tail. These results define deimi-
downregulation. These results identify the deiminationnation as a novel mechanism for antagonizing the tran-
of H3 as a novel mechanism for antagonizing the tran-scriptional induction mediated by arginine methyl-
scriptional activation mediated by arginine methylation.ation.
ResultsIntroduction
PADI4 Is a Histone H3 DeiminaseCovalent modification of the N-terminal tails of histones
We wished to examine the possibility that a member ofplays a critical role in the regulation of chromatin struc-
the PADI family of proteins (Figure 1B) is able to deimi-
nate arginines within histones. We therefore concen-*Correspondence: tk106@mole.bio.cam.ac.uk
5 These authors contributed equally to this work. trated on a nuclear member, PADI4 (Nakashima et al.,
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Figure 1. A Human Peptidyl Arginine Deiminase (PADI) Converts Arginine in Histone H3 to Citrulline
(A) The reaction catalyzed by PADIs involves the removal of an imino group from peptidyl arginine to produce peptidyl citrulline.
(B) Five PADI family members have been identified in humans, of which only PADI4 possesses an identified nuclear localization signal.
(C) Treatment of bulk histones with recombinant GST.PADI4 in the presence of calcium generates a single band containing citrulline that
corresponds to a form of histone H3 that exhibits faster migration in SDS-PAGE (marked with *).
(D) Treatment of histone H3 with recombinant GST.PADI4 lacking residues 591–663 in the presence of calcium does not generate a deiminated
band (lane 2).
2002). To test for histone deiminase activity, the PADI4 citrulline (cit, Figure 2B). The sequencing could not de-
termine whether R26 in the tail was modified. We there-protein was expressed recombinantly as a GST fusion
and added to a purified preparation of all four histones. fore used a peptide that overlaps this residue as a sub-
strate for PADI4. Mass spectrometry indicates that R26To monitor the conversion of arginines to citrulline, an
antibody was used that detects a chemically modified can also be converted to citrulline by PADI4 (Figure 4B
and Supplemental Data available at http://www.cell.version of citrulline (Senshu et al., 1992). Figure 1C
shows that this anticitrulline antibody detects histone com/cgi/content/full/118/5/545/DC1).
To monitor more specifically the deimination of H3H3 specifically, only when recombinant PADI4 and cal-
cium are added to histones (lane 3). The histone H3 in vivo we raised an antibody that recognizes deiminated
H3. The Cit-H3 antibody (Figure 3) was raised againstdetected is a faster migrating variant of H3, presumably
due to the reduction of the positive charge as a result a peptide corresponding to the tail of H3 with citrulline
present in the place of R2, R8, and R17 (Figure 3A).of arginine deimination. To ensure that the enzymatic
activity of PADI4 was responsible for the modifications Figure 3B shows that the Cit-H3 antibody recognizes
the faster migrating deiminated H3, which is generatedof H3 observed in Figure 1C lane 3, a mutant of PADI4
was expressed in which a conserved region of C-ter- when PADI4 is incubated with H3. No reactivity is ob-
served with unmodified H3 (Figure 3B) or with otherminal residues was deleted. This PADI4 mutant was
unable to generate the faster migrating deiminated his- histones treated by PADI4 (Figure 3C). Use of this anti-
body in Western blots indicates that H3 has virtuallytone H3 band (Figure 1D). These results suggest that
PADI4 is able to specifically deiminate histone H3 when undetectable levels of citrulline in cultured MCF-7 cells
(Figure 3D, lane 1). However, when PADI4 is overex-presented with all four core histones as potential sub-
strates. pressed in these cells, detection of deiminated H3 by
the Cit-H3 antibody increases substantially (Figure 3D,To map the sites of deimination we used a tailless
form of H3, which lacks the first 26 N-terminal residues. lane 2). These results confirm that endogenous H3 tail
arginine residues are deiminated by the action of PADI4.This region of H3 contains the N-terminal arginine resi-
dues that are targeted for methylation by CARM1 (Bauer
et al., 2002; Schurter et al., 2001). Figure 2A shows that Deimination Antagonizes Arginine Methylation
These results demonstrate that PADI4 has the capacityPADI4 can deiminate full-length but not the tailless ver-
sion of H3. Identification of the sites of deimination in to deiminate all four arginines in the tail of histone H3.
Three of these (R2, R17, R26) are known substratesthe H3 tail was carried out by N-terminal sequencing,
which showed that R2, R8, and R17 are converted to for the CARM1 methyltransferase. We next tested the
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Figure 2. PADI4 Deiminates Arginine Residues in the N-Terminal Tail of Histone H3
(A) Western blotting against citrulline shows recombinant GST.PADI4 has a strong preference for full-length recombinant histone H3 (lanes 1
and 2) over recombinant histone H3 lacking N-terminal tail residues 1–26 (lanes 3 and 4).
(B) Edman sequencing of unmodified (upper band) and deiminated (lower band) histone H3 reveals conversion of arginine to citrulline at
positions 2, 8, and 17 of the N-terminal tail.
possibility that the deimination process blocks the ac- two substrates: wild-type H3 tail peptide (Figure 4A,
peptide 1) and an H3 tail peptide in which argininestion of arginine methyltransferases such as CARM1. The
CARM1 methyltransferase was assayed for activity on R2, R8, and R17 were replaced by citrulline (Figure 4A,
Figure 3. Generation of an Antibody that Specifically Recognizes Deiminated Histone H3
(A) An antibody (called citH3) was raised against a peptide consisting of residues 1–21 of the histone H3 N-terminal tail.
(B) This antibody recognizes deiminated H3 in vitro (lane 3, *), but not the unmodified or control H3 (lanes 2 and 3).
(C) This antibody only recognizes a single band when all core histones are present in the deimination reaction mix.
(D) Deiminated histone H3 is virtually undetectable in MCF-7 whole-cell extract although endogenous PADI4 is expressed (lane 1), but
overexpression of PADI4 generates the deiminated form of H3 (lane 2).
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Figure 4. Deimination Is Antagonistic to Argi-
nine Methylation
(A) Peptides corresponding to residues 1–21
of histone H3 with either arginine or citrulline
at positions 2, 8, and 17 were treated with
the CARM1 methyltransferase in the absence
or presence of [3H]-S-adenosyl-L-methionine
(SAM) as indicated. CARM1 transferred ra-
dioactive methyl groups to the arginine-con-
taining peptide but not the citrulline-con-
taining peptide.
(B) Methylated and unmethylated peptides
corresponding to the histone H3 tail were
treated with recombinant PADI4 in the pres-
ence of calcium. MALDI-reTOF mass spec-
trometry revealed the presence of citrulline in
the peptides indicated. N-terminal chemical
sequencing was then used to quantitate the
relative amounts of arginine, citrulline, and
dimethylated arginine residues in each pep-
tide, by comparison to the quantitated syn-
thetic peptide standard. The following ar-
ginine to citrulline conversions could be
calculated: Arg2: 20%; Arg8: 91%; Arg17:
58%; Arg26: 52%. No detectable conversion
of 2Me-Arg 2, 17, 26 to Cit was observed (see
Supplemental Data available on Cell website).
(C) Purified histone H3 treated with recombi-
nant PADI4 in the presence of calcium and
probed with a monoclonal antibody specific
to monomethyl arginine show loss of mono-
methylation as the reaction progresses.
peptide 2). Figure 4A shows that CARM1 cannot methyl- tide could not be synthesized because the requisite
monomethyl arginine derivative does not exist. Figureate an H3 tail containing citrulline, demonstrating deimi-
nation blocks methylation by CARM1. 4B shows that PADI4 is unable to convert either asym-
metric dimethyl R2, R17, or R26 or symmetric dimethylWe next asked whether methylated arginine could be
a substrate for PADI4. Methylation of arginines can be R17 to citrulline (see also Supplemental Data available
on Cell website). This leaves open the possibility thatmonomethyl, symmetric dimethyl, or asymmetric di-
methyl (Bannister et al., 2002). Mass spectrometry has monomethyl arginine may be deiminated by PADI4.
Since a monomethyl arginine peptide could not beidentified the presence of monomethyl arginine in bulk
preparation of histones whereas antibodies raised made, we explored this possibility using an antibody that
detects monomethyl arginine in a context independentagainst asymmetric dimethyl arginine have detected this
modification appearing on chromatin following stimula- manner. Figure 4C shows that this antibody can detect
monomethyl arginine in purified H3. Deimination of H3tion of cells by estrogen (Bauer et al., 2002; Ma et al.,
2001; Strahl et al., 2001; Zhang et al., 2003). To establish by incubation with PADI4 results in a significant loss
signal from this monomethyl arginine antibody. Theseif PADI4 can deiminate methylated arginines, peptides
were made which contain symmetrically or asymmetri- results suggest that PADI4 is able to convert peptidyl
monomethyl arginine to citrulline. Confirmation of thiscally dimethylated R17 H3. A monomethyl R17 H3 pep-
Deimination of Histones
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Figure 5. PADI4 Targeted to the Endogenous
VEGF-A Promoter Represses Hormone-
Mediated Transcriptional Activation
(A) An endogenous gene, VEGF-A, was used
as a reporter to test repression by PADI4. The
VEGF-A promoter contains binding sites for
two zinc finger proteins (ZFa and -b) as indi-
cated. These zinc fingers were fused to
PADI4, the estrogen receptor (ER) ligand
binding domain, thyroid hormone receptor li-
gand binding domain (TR) or p65. Control
constructs were made targeting PADI4 to a
non-VEGF-A promoter (ZFPmut), encoding a
GFP PADI4 fusion (nonchromatin binding)
and a catalytically inactive PADI4 (PADI4mut).
All PADI4 constructs were expressed at equiv-
alent levels. Constructs were transfected
into human embryonic kidney 293 cells in
the combinations indicated. Production of
VEGF-A mRNA and secreted protein were as-
sayed 72 hr posttransfection. mRNA levels
were normalized against GAPDH mRNA levels.
(B) Transcriptional activation by recruitment
of the estrogen receptor in the presence of
estrogen (E2) is reduced by simultaneous re-
cruitment of PADI4 but recruitment of PADI4
does not affect p65-mediated activation. Nor-
malized activity of the VEGF-A gene on the y
axis was measured by real-time PCR with a
Taqman probe. Bars represent (left to right):
basal expression of the VEGF-A gene in the
presence of the ER construct; activation by
the ER construct in the presence of estradiol;
repression of ER/E2 activation by recruitment
of PADI4; activation by the p65 construct; p65
activation in the presence of PADI4.
(C) PADI4 also reduces the ability of thyroid hormone receptor to activate the VEGF-A gene in the presence of thyroid hormone (T3). This
effect is not emulated by mutant PADI4 or by PADI4 constructs that are not targeted to the VEGF-A promoter. Gene expression was assayed
(y axis) by ELISA-based detection of secreted VEGF-A protein. Bars represent (left to right): expression of VEGF-A in the presence of the TR
construct; activation by TR and T3; basal expression of VEGF-A; basal expression with T3 but without the TR construct; activation by TR and
T3 in the presence of control vector; repression of TR/T3 activation by PADI4 recruitment; activation by TR/T3 in the presence of the nontargeting
PADI4 construct; activation by TR/T3 in the presence of the targeted PADI4 mutant; activation by TR/T3 in the presence of GFP-PADI4.
awaits the availability of reagents to generate mono- cific zinc finger DNA binding domain (ZFa). The PADI4
deiminase was delivered in parallel fused to a secondmethylated H3 peptides or monomethyl arginine histone
H3 specific antibodies. VEGF-A targeting zinc finger DNA binding domain (ZFb),
directing this domain to two sites in close proximity to
the first (ZFa) on the VEGF-A promoter (Figure 5A) toPADI4 Represses Hormone-Receptor
Regulated Transcription monitor its effect on hormone-dependent activation. As
a control for the specificity of the effects of PADI4 onGiven the ability of PADI4 to block arginine methylation
within H3, we next sought to establish if PADI4 can hormone-dependent activation, the PADI4 zinc finger
protein fusion was used to challenge the transcriptionalregulate transcription via its enzymatic activity. To char-
acterize the functions of PADI4 in regulating transcrip- activation of VEGF-A by a p65 (RelA) zinc finger fusion,
which stimulates VEGF-A transcription in a hormone-tion, we utilized a system that has been used for the
analysis of other chromatin-modifying enzymes. Directly independent manner.
Figure 5B shows that the activation of VEGF-A by thetargeting the lysine methyltransferases Suv39H1 and
G9a to an endogenous promoter via an engineered zinc ER-ZFa in the presence of E2 hormone is repressed
by the PADI4-ZFb. In contrast, PADI4-ZFb is unable tofinger DNA binding domain has shown that these en-
zymes can specifically induce transcriptional repression repress the constitutive activity of the p65-ZF fusion.
PADI4-ZFb is also unable to repress transcriptional acti-of endogenous chromatinized genes in vivo via their
enzymatic activities (Snowden et al., 2002). This system vation mediated by a VP16-ZFa fusion (data not shown).
Figure 5C shows that PADI4-ZFb can also repress thewas used to ask whether PADI4 is a repressor and if
repression is specific to the nuclear hormone-signaling thyroid hormone dependent activation of the VEGF-A
promoter. Significantly, repression of TR-ZFa mediatedpathway, which is known to be regulated by arginine
methylation (Figure 5). The endogenous VEGF-A gene transcriptional activation by PADI4-ZFb occurs in trans
as it is dependent on the correct targeting of the deimi-was activated by the estrogen or thyroid hormone recep-
tor ligand binding domains targeted by a VEGF-A spe- nase activity to the promoter, as both a GFP PADI4
Cell
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fusion and a non-VEGF-A targeting PADI4 zinc finger
fusion (ZFmut) do not antagonize TR-mediated tran-
scriptional activation of VEGF-A. PADI4-ZFb mediated
repression is also primarily dependent on its deiminase
activity since a mutant PADI4 that has lost the ability
to deiminate H3 (Figure 2B) has significantly reduced
repression potential. The level of repression achieved
by targeting PADI4 to the endogenous VEGF-A promoter
is equivalent to that achieved by targeting the lysine
methyltransferases Suv39h1 and G9a to the same pro-
moter (Snowden et al., 2002). These results indicate
that targeting of PADI4 is sufficient to repress hormone-
dependent transcriptional activation in a manner that
depends on the catalytic activity of the enzyme, while
not affecting transcriptional activation by other classes
of transactivators such as NF-B.
Deimination of the pS2 Promoter Occurs
during Transcriptional Downregulation
We next examined an endogenous promoter whose re-
sponse to hormone induction is regulated by arginine
methylation. Analysis of the pS2 promoter has shown
that dimethylation of R17 of H3 appears on chromatin
when the gene is activated by estrogen (Bauer et al.,
2002; Ma et al., 2001) and that this modification dimin-
ishes when the gene is disengaged from RNA polymer-
ase II (Metivier et al., 2003). Consistent with a role for
the PADI4 enzyme in hormone regulation, the levels of
PADI4 in MCF-7 cells rise in response to estrogen (Figure
6A). Chromatin immunoprecipitation with the Cit-H3 an-
tibody and a PADI4 antibody shows that the deiminating
enzyme and the modification it catalyzes both appear
on the chromatin of the pS2 promoter in response to
estrogen (Figures 6B and 6C). Their appearance coin-
cides with the disengagement of RNA polymerase II
from the pS2 promoter (Figure 6D), consistent with the
repressive function of PADI4 highlighted in Figure 5. In
contrast, dimethylation of R17 of histone H3 appears
when RNA polymerase II is engaged with the promoter,
consistent with methylation having a positive effect on
transcription (Figure 6E)
Taken together the analysis of the pS2 promoter in-
dicates that deimination (1) is implicated in estrogen-
mediated signaling, like arginine methylation and (2) ap-
pears on the promoter when the gene is disengaged
from RNA polymerase II and arginine dimethylation of
H3 is at a minimum. These results suggest that deimina-
tion and arginine methylation have opposing effects on
gene expression.
Discussion
Here, we report the identification of PADI4 as a histone
H3 specific arginine deiminase with a potential to re-
Figure 6. PADI4 Is Recruited to the pS2 Promoter in Response to
press transcription. Analysis of the estrogen-regulated
pS2 promoter demonstrates that deimination of H3 has
Estrogen Stimulation and Deiminates Histone H3 opposing features to arginine methylation: citrulline ap-
pears in H3 when the gene is downregulated, whereas(A) PADI4 levels in MCF-7 cells increase on induction with estrogen
when compared to a GAPDH loading control.
(B–E) Chromatin immunoprecipitation experiments using antibodies
against PADI4, deiminated H3 (citH3), RNA polymerase II and di-
(bound) pS2 promoter sequence compared to input chromatin weremethyl R17 of H3 were carried out on the pS2 promoter in MCF-7
determined using real-time PCR. Error bars represent the standardcells before estrogen stimulation (UI) and at the indicated times after
deviation of multiple analyses.the addition of estrogen. Relative amounts of immunoprecipitated
Deimination of Histones
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Figure 7. A Model for the Antagonism of Histone Arginine Methylation by PADI4-Mediated Deimination
Deimination can block methylation of unmethylated arginine residues of histone H3 (I). Monomethylated arginine residues may be a substrate
for deimination, effectively making this a demethylating activity (II). Deimination may be reversed by histone replacement or a distinct enzymatic
activity. Dimethylated arginines cannot be deiminated by PADI4, thus dimethylation may act as a positive signal for transcription that cannot
be reversed by a deiminating pathway
arginine methylation coincides with the transcriptionally be necessary during hormone stimulation. If PADI4 can
reverse the monomethyl mark, it may prevent furtheractive state. Together these data strongly suggest that
deimination represents a novel pathway that counter- stimulation of the promoter by CARM1. On the other
hand, if CARM1 converts monomethyl to dimethyl argi-acts the function of arginine methylation. The precise
mechanism of this antagonism is still to be determined. nine, protection from deimination is immediately con-
ferred to the dimethylated residue.The results presented here provide insight into possible
pathways by which deimination can oppose the methyl- The results presented here do not resolve the issue
of how dimethylation of arginines is reversed. Dimethy-ation of arginines. Figure 7 suggests two such pathways.
In one pathway, PADI4 has the potential to block any lation has been shown to occur in cycles following es-
trogen stimulation so mechanisms must exist to de-methyltransferase from signaling to arginines, since
conversion to citrulline eliminates the possibility of methylate arginines. Various novel pathways may be
operational including the existence of a demethylasemethylation taking place. This block of methylation (I,
Figure 7) may occur in either a spatial or a temporal activity, or the replacement of a dimethylated histone
with an unmodified variant. The possibility also exists,sense. A spatial block (deimination of specific nucleo-
somes) may limit the function of arginine methylation to however, that PADI4 itself may be able to deiminate
dimethylated arginine when modified or part of a specificlocalized regions within a gene. A temporal block may
allow the ordered appearance of arginine methylation complex in vivo. Alternatively, another PADI family mem-
ber may have the potential to carry out this conversion.on a given gene during a hormone response. The block
to methylation by deimination could also occur on a Figure 6 clearly demonstrates that the appearance of
citrulline on the pS2 promoter is transient. This suggestsgene-to-gene basis, rather than within a gene. The ac-
tion of PADI4 on certain genes may occlude them from that mechanisms exist that will rapidly remove citrulline
after it appears in the H3 tail. The removal of citrullinebeing responsive to activation by arginine methylation.
In a second pathway, PADI4 may reverse a methyla- may be mediated by aminotransferase enzymes that
can convert citrulline back into arginine. Biosynthetiction event that has already taken place (II, Figure 7). Our
results raise the possibility that monomethyl arginine enzymes that can catalyze this type of reaction are
known to exist (Bannister et al., 2002). There may be(and not dimethyl arginine) is a substrate for PADI4 dei-
mination. Thus, PADI4 may act as an enzyme, which in homologs of these that are active on peptidyl substrates
and could function on citrulline in histones. Alternatively,essence, can act as a demethylase for a specific methyl-
arginine state. a histone variant replacement pathway may be opera-
tional which exchanges the deiminated histone with oneThe functional significance of monoarginine methyla-
tion is not known, but this is the methyl state found containing arginines. This would mean that the block or
reversal of arginine methylation by deimination can itselfexclusively when bulk histones are analyzed by mass
spectrometry (Strahl et al., 2001; Zhang et al., 2003). be reversed by the deposition of an unmodified histone
variant such as histone H3.3. Further rounds of arginineIn contrast dimethylation is detected by antibodies on
genes that are activated following hormone induction. methylation would then be possible.
The results presented here uncover arginine deimina-This raises the possibility that the monomethyl state
detected in bulk histones is the “poised” state. Further tion as a novel pathway by which methylation of argi-
nines within histones can be reversed or completelymethylation by CARM1 to generate a dimethyl state may
Cell
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incubator at 37C. For transfections, HEK293 cells were plated inblocked. Thus, the deiminating activity of the PADI4
6-well plates at a density of 500,000 cells/well and transfected 1repressor represents an antagonistic pathway to the
day later using Lipofectamine 2000 reagent (Gibco-BRL, MD) ac-positive transcriptional signal transmitted by arginine
cording to manufacturers recommendations, using 9 l of Lipofect-
methylation. amine 2000 reagent and 1.5 g total plasmid DNA per well. The
medium was removed and replaced with fresh medium 6–12 hr
Experimental Procedures posttransfection and hormone stimulations were performed after
24 hr. Transfection efficiency was assessed in each independent
In Vitro Reactions experiment via the use of a GFP expression plasmid control, in all
GST.PADI4 constructs were expressed at 30C in 2TY media in 0.1 experiments an apparent efficiency of 80%–90% GFP positive cells
mM IPTG from pGEX6p and purified using glutathione-Sepharose was observed.
resin. Deimination reactions were carried out using bead-bound HEK293 cells were lysed and total RNA prepared using the high
enzyme in 50 mM HEPES [pH 7.5], 2 mM DTT, and 10 mM CaCl2 at pure RNA isolation kit (Roche) according to manufacturers recom-
30C. Substrates were bulk calf thymus histones (Sigma), purified mendations. RNA (25 ng) was used in real-time quantitative RT-PCR
calf thymus histone H3 (Roche), recombinant histone H3 and tailless analysis using TaqMan chemistry in a 96-well format on an ABI 7700
histone H3 lacking residues 1–26, and various peptides. Peptides SDS machine (PerkinElmer Life Sciences) as described previously
described in the manuscript were synthesized by Graham Bloom- (Snowden et al., 2002). Briefly, reverse transcription was performed
berg at the University of Bristol. at 48C for 30 min using MultiScribe reverse transcriptase (Perkin-
GST.CARM1 was expressed and purified as above. GST.CARM1 Elmer Life Sciences). Following a 10 min denaturation at 95C, PCR
was eluted using 50 mM reduced glutathione then dialyzed against amplification using AmpliGold DNA polymerase was conducted for
10% glycerol in PBS. Methylation reactions were carried out in 5% 40 cycles at 95C for 15 s and at 60C for 1 min. Primer/probes used
glycerol, PBS with [3H]S-adenosyl-L-methionine. CARM1 peptide were as described previously (Snowden et al., 2002). The results
reactions were bound to p81 cation exchange membrane (What- were analyzed using SDS Version 1.6.3 software.
man), washed with 50 mM carbonate buffer [pH 9.2], and incorpo- Secreted VEGF-A in the tissue culture media by transfected
rated radioactivity measured by scintillation counting (Daujat et HEK293 cells was assayed 48 hr after hormone stimulation, using
al., 2002). a human VEGF-A ELISA kit (R&D systems) in duplicate according
HEK293 and MCF-7 cells were maintained in Dulbecco’s modified to manufacturers recommendations.
Eagle’s medium (DMEM, Gibco-BRL) supplemented with 10% fetal
calf serum (FCS, Gibco-BRL) at 37C and 5% CO2. Cells were trans-
Chromatin Immunoprecipitations (ChIPs)fected with pcDNA3.HA.PADI4 using FuGENE transfection reagent
and Real-Time PCR Analysis(Roche) according to the manufacturer’s instructions. 48 hr post-
MCF-7 cells were maintained in Dulbecco’s modified Eagle’s me-transfection cells were lysed in 50 mM HEPES [pH 7.5], 2 mM DTT,
dium (DMEM, Gibco-BRL) supplemented with 10% FBS (Gibco-150 mM NaCl, 0.5% NP-40, and HA.PADI4 was immunoprecipitated
BRL) at 37C and 5% CO2. ChIP experiments were performed withusing an anti-HA antibody (Abcam ab9110). Immunoprecipitated
modifications of the procedure described previously (Dedon et al.,bead-bound protein was washed with lysis buffer and reactions
1991; Orlando et al., 1997). Cells were grown in phenol red-freecarried in vitro out as above. Whole-cell extracts were made by
DMEM (Gibco-BRL) supplemented with 5% charcoal-dextran-lysing MCF-7 cells in RIPA buffer (50 mM Tris [pH 8.0], 150 mM
stripped FBS for 5 days. Following the addition of either ethanol asNaCl, 1% NP-40, 0.5% deoxycholate).
control (uninduced) or 200 nM 17-estradiol (E2) for indicated times,
cells were crosslinked with 1% formaldehyde (Sigma) at room tem-Antibodies
perature for 15 min, rinsed twice with ice-cold PBS [pH 7.4], andPolyclonal -PADI4 was raised by immunizing a rabbit with purified
collected in PBS before a centrifugation for 5 min at 2000 g. CellsGST-PADI4 then affinity purifying the antibody from whole serum
were then lysed in 1 ml of ChIP lysis buffer (50 mM Tris-HCl [pHwith GST-PADI4 (Nakashima et al., 2002). Polyclonal -modified
8.1], 1% SDS, 10 mM EDTA) and sonicated for 20 min with 30 s oncitrulline was purchased from Upstate (Cat.no.17-347) and the modi-
and off cycles at high settings (Bioruptor, Diagenode) to producefication of membrane bound citrulline carried out according to the
chromatin fragments of 0.5 kb on average. After centrifugation andsupplier’s instructions. The monoclonal antibody recognizing con-
quantification, 50 l of the supernatants were used as inputs andtext-independent monomethyl arginine was purchased from Abcam
the remainder was diluted 10-fold in IP buffer (10 mM Tris-HCl [pH(ab415), as was the antibody against dimethyl R17 of H3 (ab8284).
8.1], 1% Triton X-100, 0.1% deoxycholate, 0.1% SDS, 90 mM NaCl,The polyclonal citH3 antibody was raised in collaboration with Ab-
2 mM EDTA) and an equivalent of 2  106 cells per time pointcam (ab5103) by immunizing a rabbit with a peptide of the sequence
was subjected to immunoprecipitation overnight at 4C after 2 hrACitTKQTACitKSTGGKAPCitKQLA and purifying the antibody
preclearing with 20l of a 50% protein A/G-Sepharose beads (Amer-against the same peptide. The monoclonal antibody against RNA
sham) slurry. These beads were prepared by two washings in IPpolymerase II was purchased from Covance (Cat. no. MMS-126R-
buffer and a 3 hr incubation with 25 g shared salmon DNA and500).
200 g BSA per ml of solution in IP buffer. The beads were then
resuspended 1:1 in IP buffer and used for ChIPs. 4 l of anti-PADI4,Mass Spectrometry and Edman Sequencing
6 l of anti-citH3, 5 l of anti-H3.3, and 4 l of anti-RNA polymerasePeptides corresponding to the N-terminal tail of Histone H3 were
II were used in each ChIP experiment. Complexes were then recov-analyzed by MALDI-ReTOF mass spectrometry (UltraFlex TOF/TOF;
ered by 2 hr incubation at 4C with 20l of the protein A/G SepharoseBruker Daltonics; Billerica, MA) as described (Erdjument-Bromage
beads solution. Precipitates were washed, removed from the beads,et al., 1998). Chemical sequencing was done using a Procise 494
and DNA was recovered as described previously (Daujat et al., 2002;instrument from Applied Biosystems (AB), also as described
Dedon et al., 1991; Orlando et al., 1997). Quantitative real-time PCR(Tempst et al., 1994). Stepwise liberated phenylthiohydantoin (PTH)
were performed using SybrGreen (Applied Biosystems) as a markerderivatives of amino acids were identified using an “on-line” HPLC
for DNA amplification on an ABI Prism 7000 apparatus (Appliedsystem (AB) equipped with a PTH C18 (2.1  220 mm; 5 micron
Biosystems). The 5 to 3 sequences of the primers used to detectparticle size) column (AB). The retention times of the PTH-Citrulline
the presence of human pS2 promoter fragments are: forward-355(Cit), and PTH-Di-methyl Arginine were established by analyzing
CCGGCCATCTCTCACTATGAA and reverse-295 CCTCCCGCCAGa synthetic peptide with the following sequence: Ala Ala Arg Ala
GGTAAATAC.2Me(asym)-Arg Ala Cit Ala 2Me(sym)-Arg Asp Asp Asp Asp. Fmoc-
Citrulline was purchased from Anaspec Inc CA, USA and 2Me(sym
and asym)-Arginines were from Bachem Biosciences Inc., PA, USA. Acknowledgments
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